Steffi Oesterreich, PhD
Professor of Pharmacology and Chemical Biology

Dr. Oesterreich is the Director of Education at the Women's Cancer Research Center, a collaboration between the Magee Women's Research Institute and University of Pittsburgh Cancer Institute. She is a new member of the Cellular and Molecular Pathology Graduate Training Program.

Office Location:
204 Craft Avenue, Room B410
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-641-8555


  • PhD - Humboldt University, Berlin - 1992

Research Interests

Dr. Oesterreich’s research is focused on endocrine resistance in breast cancer, including the analysis of aberrant genetic and epigenetic changes. She utilizes cell line models, mouse models, and clinical samples. More recently her group has begun to study the role of nuclear receptors including ER and PR in ovarian cancer development and progression.

Awards and Honors

  • HOECHST PhD Award - 1990
  • Deutscher Akademischer Austauschdienst Fellowship – 1992
  • German Academic Exchange Fellowship
  • Postdoctoral Fellowship, Susan G. Komen Breast Cancer - 1993
  • Howard Hughes Medical Institute, New Faculty Start-Up - 1997
  • Howard Temin (K01), Career Development Award (NIH/NCI) - 1999
  • T.T. Chao Scholar Award - 2000
  • Women’s Health Research Award (Women in Endocrinology) - 2002
  • Alexander von Humboldt Fellowship - 2006

Selected Publications

View Dr. Oesterreich's publications on PubMed

  • Malik S, Jiang J, Garee J, Verdin E, Lee AV, O’Malley BW, Zhang W, Belaguli NS, Oesterreich S. Intricate Interplay between HDAC7 and FoxA1 in estrogen-mediated repression of RPRM. Mol Cell Biol. 2010, 30:399-412, PMID: 19917725.
  • Garee J and Oesterreich S. SAFB1’s Multiple Functions in Biological Control — Lots Still to Be Done. Review. J Cell Biochem. 2010, 109:312-9, PMID: 20014070.
  • Hammerich-Hille S, Tsimelzon A, Kaipparettu BA, Creighton C, Jiang S, Polo JM, Melnick A, Meyer R, Oesterreich S. SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. J Biol Chem 2010, 285:3608-16, PMID: 19901029.
  • Pathiraja TN, Stearns V, Oesterreich S. Epigenetic Regulation in estrogen receptor positive breast cancer – role in treatment response. J Mammary Gland Biol Neoplasia 2010, Epub ahead of print. PMID: 20101445.
  • Dearth RK, Delgado DA, Hiney JK, Pathiraja T, Oesterreich S, Medina D, Dees LW and Lee AV. Parity-induced reduction in circulating growth hormone (GH) is associated with altered mammary gland signaling in two rat strains: Implications for pregnancy protection from breast cancer. Cancer Prevention Res. 2010, 3:312-21, PMID: 20145191.
  • Karmakar S, Gao T, Pace MC, Oesterreich S, Smith CL. Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor. Mol Endo 2010, 24:1187-202, PMID: 20392877.
  • Oesterreich S, Lee AV, Davidson NE. Is It Time To ReSET the Standard for Estrogen Receptor Testing in Breast Cancer? J Clin Oncol 28:41-1-41-3. 2010. PMID: 20697070.
  • Pathiraja TN, Shetty TB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S. Progesterone receptor isoform-specific promoter methylation — Association of PRA methylation with worse outcome in breast cancer patients. Clin Cancer Res. 17:4177-4186. 2011. PMID: 21459801.
  • Spears M, Oesterreich S, Migliaccio I, Guiterrez C, Hilsenbeck S, Quintayo MA, Pedraza J, Munro AF, Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM. The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2011 in press. PMID: 21390497.
  • Lachapelle S, Oesterreich S, Lebel M. Loss of the helicase function of the Werner gene product increases perinatal lethality of mice lacking the Scaffold Attachment Factor B1 and inhibits mouse embryonic fibroblast immortalization. Aging. 3:277-290. 2011.
  • Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2011 in press. PMID: 21541704.
  • Garee JP, Meyer R, Oesterreich S. Co-repressor activity of scaffold attachment factor B1 requires sumoylation. Biochem Biophys Res Commun. 2011 May 20;408(4):516-22. PMID: 21527249.
  • Phillips S, Richter A, Oesterreich S, Rae JM, Flockhart DA, Perumal NB, Skaar TC. Functional characterization of a genetic polymorphism in the promoter of the ESR2 gene. Horm Cancer 2011, OCr 7. In press. PMID: 21979797.
  • Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3β Phosphorylation Site and Is Associated with Altered Tamoxifen Response in Bone. Mol Endo Dec 2011. PMID: 22174377.
  • Watters RJ, Benos PV, Oesterreich S. To bind or not to bind - FoxA1 determines estrogen receptor action in breast cancer progression. Breast Cancer Res.14(3):312. 2012. PMID: 22713214.
  • Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SE. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012 Jun 16. PMID: 22706629.
  • Philips S, Rae JM, Oesterreich S, Hayes DF, Stearns V, Henry NL, Storniolo AM, Flockhart DA, Skaar TC. Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes. Front Pharmacol. 2012;3:54. PMID: 22479249.
  • Osmanbeyoglu HU, Hartmaier RJ, Oesterreich S, Lu X. Improving ChIP-seq peak-calling for functional co-regulator binding by integrating multiple sources of biological information. BMC Genomics. 13 Suppl 1:S1. 2012, PMID: 22369349.
  • Watters RJ, Benos PV, Oesterreich S. To bind or not to bind - FoxA1 determines estrogen receptor action in breast cancer progression. Breast Cancer Res. 2012 Jun 19;14(3):312. PMID: 22713214.